Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Elimusertib (BAY-1895344) 是一种可口服的选择性ATR 抑制剂,IC50值为 7 nM。它具有抗肿瘤活性,可研究实体瘤和淋巴瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 358 | 现货 | ||
2 mg | ¥ 522 | 现货 | ||
5 mg | ¥ 863 | 现货 | ||
10 mg | ¥ 1,330 | 现货 | ||
25 mg | ¥ 2,630 | 现货 | ||
50 mg | ¥ 3,860 | 现货 | ||
100 mg | ¥ 5,490 | 现货 | ||
500 mg | ¥ 10,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 980 | 现货 |
产品描述 | Elimusertib (BAY-1895344) is a potent, highly selective and orally available ATR inhibitor with an IC50 of 7 nM.Elimusertib shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride. |
靶点活性 | ATR:7 nM (IC50) |
体内活性 | The novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability.?Potent antiproliferative activity was demonstrated in a broad spectrum of human tumor cell lines.?BAY 1895344 exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies.?The combination of BAY 1895344 with DNA damage-inducing chemotherapy or external beam radiotherapy (EBRT) showed synergistic antitumor activity.?Combination treatment with BAY 1895344 and DDR inhibitors achieved strong synergistic antiproliferative activity in vitro, and combined inhibition of ATR and PARP signaling using olaparib demonstrated synergistic antitumor activity in vivo Furthermore, the combination of BAY 1895344 with the novel, nonsteroidal androgen receptor antagonist darolutamide resulted in significantly improved antitumor efficacy compared with respective single-agent treatments in hormone-dependent prostate cancer,?and addition of EBRT resulted in even further enhanced antitumor efficacy[1]. |
别名 | BAY-1895344 |
分子量 | 375.43 |
分子式 | C20H21N7O |
CAS No. | 1876467-74-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (29.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6636 mL | 13.3181 mL | 26.6361 mL | 66.5903 mL |
5 mM | 0.5327 mL | 2.6636 mL | 5.3272 mL | 13.3181 mL | |
10 mM | 0.2664 mL | 1.3318 mL | 2.6636 mL | 6.659 mL | |
20 mM | 0.1332 mL | 0.6659 mL | 1.3318 mL | 3.3295 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Elimusertib 1876467-74-1 DNA Damage/DNA Repair PI3K/Akt/mTOR signaling ATM/ATR response damage stress Inhibitor tumors DNA instability lymphomas inhibit solid BAY-1895344 ATM and RAD3 related Ataxia telangiectasia mutated replication genomic BAY1895344 repair BAY 1895344 inhibitor